Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Carcinoembryonic antigen (CEA) is an important oncomarker for the detection of breast cancer.
|
31247453 |
2019 |
Breast Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Patients with high levels of CTC double-marked by KRT19 and CEACAM5 mRNA had shorter DMFS (P < 0.0001) and OS (P = 0.016) for patients with breast cancer.
|
30535933 |
2019 |
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Although expression of CEA largely ceases prior to birth, several human epithelial cancers, including colorectal, gastric, squamous esophageal, and breast carcinomas have been known to overexpress CEA, suggesting its potential as an immunotherapeutic target.
|
30666318 |
2019 |
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Authors investigated the expression level of miRNAs (miRNA-21, miRNA-126, and miRNA-155) to evaluate their role as diagnostic and prognostic markers for breast cancer compared with other commonly used protein-based markers (CEA and CA15-3).
|
30825229 |
2019 |
Breast Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
On multivariable analyses, subtype changes were more common in high-grade breast cancer (P < 0.001; OR, 1.077; 95% CI, 1.031-1.113) and CEA ≥ 5 (P = 0.032; OR, 2.658; 95% CI, 1.088-6.490).
|
31742206 |
2019 |
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Preoperative CA15-3 and CEA elevation are significant prognostic factors for luminal breast cancer, but they were not significant factors for TNBC.
|
31312932 |
2019 |
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The area under curve (AUC) of CEA, CA153, and FER for distinguishing patients with breast cancer and subjects with non-breast cancer was 0.688 (95% CI: 0.656-0.721), 0.609 (95% CI: 0.574-0.645), and 0.623 (95% CI: 0.586-0.660), respectively.
|
30843272 |
2019 |
Breast Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
CEA mRNA evaluation is diagnostically valuable as a breast cancer marker.
|
31653144 |
2019 |
Breast Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Additionally, the tumor markers for breast cancer (CA 15-3 and CEA) were analyzed in both groups.
|
31412345 |
2019 |
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
cfDNA CIN yields a higher accuracy in monitoring breast cancer recurrence compared to traditional biomarkers (CA15-3 and CEA), especially for biomarker-negative patients.
|
31364001 |
2019 |
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Various tumor serum markers, such as carcinoembryonic antigen (CEA), pro-gastrin-releasing peptide (ProGRP), neuron-specific enolase (NSE), and cancer antigen 15-3 (CA15-3), serve not only as prognostic indicators in lung and breast cancer but also as risk factors for IM development.
|
31285868 |
2019 |
Breast Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
These findings suggest that CEA and CA15-3 levels might be useful for predicting the prognosis of patients with operable early breast cancer irrespective of the subtype.
|
29433529 |
2018 |
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Diagnostic Value of Serum Concentration and Integrity of Circulating Cell-Free DNA in Breast Cancer: A Comparative Study With CEA and CA15-3.
|
29701836 |
2018 |
Breast Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In the present study, preoperative CEA and CA15-3 serum levels were evaluated in the prediction of the prognosis for young patients with breast cancer.
|
30214602 |
2018 |
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Oncolytic MV-Edm derivatives are genetically engineered to express the human carcinoembryonic antigen (MV-CEA virus) or the human sodium iodide symporter (MV-NIS virus) and are currently being tested in clinical trials against ovarian cancer, glioblastoma multiforme, multiple myeloma, mesothelioma, head and neck cancer, breast cancer and malignant peripheral nerve sheath tumors.
|
28228086 |
2018 |
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Carcinoembryonic antigen (CEA) is one of the tumor markers available for evaluating disease progression status after initial therapy and monitoring subsequent treatment modalities in colorectal, gastrointestinal, lung, and breast carcinoma.
|
29611386 |
2018 |
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
While miR-34a provides valuable information for diagnosis and staging, combination with tumor markers CA15-3 or CEA improves the sensitivity for breast cancer detection.
|
29854296 |
2018 |
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
This meta-analysis showed that elevated serum CA15-3 or CEA was associated with poor DFS and OS in patients with breast cancer, and they should be tested anytime if possible.
|
29854028 |
2018 |
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
To identify surrogate markers for prognosis of breast cancer patients with non-pathological complete response (non-pCR) to neoadjuvant chemotherapy (NAC), our investigation focused on the serum levels of carcinoembryonic antigen (CEA) and carbohydrate antigen (CA15-3) as well as clinicopathological factors both before and after NAC.
|
29936704 |
2018 |
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In the experiments, CA153, CA125 and CEA are selected as the models of breast cancer biomarkers, which can be simultaneously detected of in human serum with an excellently specificity and a high sensitivity.
|
30029406 |
2018 |
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The positivity of miR-21, miR-155, and miR-365 was high compared to CA 153 and CEA in breast cancer.
|
28203552 |
2017 |
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
High expression of CEACAM19, a new member of carcinoembryonic antigen gene family, in patients with breast cancer.
|
27909883 |
2017 |
Breast Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In the present study, preoperative serum levels of CEA, CA125 and CA15-3 were significantly higher in patients with breast cancer than controls subjects.
|
28969044 |
2017 |
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Finally, the biosensor has been used to detect CEA in colon and breast cancer clinical samples with satisfactory results.
|
28112857 |
2017 |
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Receiver operating characteristic (ROC) curve was used to assess the diagnostic power of plasma linc-ROR, carcinoembryonic antigen (CEA) and carbohydrate antigen (CA)153 for breast cancer.
|
28869448 |
2017 |